Quality of life issues in non-small cell lung cancer

References

• Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2,533–543 (2001).
   PubMed Web of Science ®Google Scholar
• Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai SH. Health-related quality of life in non-small cell lung cancer: methodologic issues in randomised controlled trials. J: Gun. Oncol. 21, 2982–2992 (2003).
   Google Scholar
• Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar Mon behalf of the CHART Steering Committee. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomised multicentre trial. Lancet350, 161–165 (1997).
   PubMed Web of Science ®Google Scholar
• Cullen MET, Billingham LJ, Woodruffe CM et al Mitomycin, ifosfamide and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life.J Gun. Oncol. 17,3188–3194 (1999).
   Google Scholar
• Helsing M, Bergman B, Thaning L, Hero U. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised Phase III trial. Eur. Cancer34, 1036–1044 (1998).
   Google Scholar
• Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer24, 17–24 (1999).
   PubMed Web of Science ®Google Scholar
• Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) versus BSC in inoperable non-small cell lung cancer — a randomised trial with quality of life as the primary outcome. Br. J: Cancer 83, 447–453 (2000).
   PubMedGoogle Scholar
• Ranson M, Davidson N, Nicolson M et al. Randomised trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. Natl Cancer Inst. 92,1074–1080 (2000).
   Google Scholar
• Roszkowski K, Pluzanska A, Krzakowski M et al. A multicenter randomised Phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or nonresectable localized non-small cell lung cancer (NSCLC). Lung Cancer27, 145–157 (2000).
   PubMed Web of Science ®Google Scholar
• Gridelli C. The ELVIS trial: a Phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Oncologist 6\(Suppl. 1), 4–7 (2001).
   Google Scholar
• Crawford J, O'Rourke M, Schiller JH et al Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer. J: Clin. Oncol 14,2774–2784 (1996).
   Google Scholar
• Buccheri G, Ferrigno D. Efficacy of platinum-based regimens in non-small cell lung cancer: a negative report from the Cuneo Lung Cancer Study Group. Lung-Cancer18,57–70 (1997).
   PubMedGoogle Scholar
• Giaccone G, Splinter TAW, Debruyne C et al Randomised study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. Clin. Oncol 16,2133–2141 (1998).
   Web of Science ®Google Scholar
• Cardenal F, Lopez-Cabrerizo MP, Anton A et al Randomised Phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. 1 Clin. OncoL 17,12–18 (1999).
   Google Scholar
• Comella P, Frasci G, Panza N et al Cisplatin, gemcitabine and vinorelbine combination therapy in advanced non-small cell lung cancer: a Phase II randomized study of the Southern Italy Co-operative Oncology Group. J: Clin. Oncol 17,1526–1534 (1999).
   Google Scholar
• Crino L, Scagliotti GV, Ricci C et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer: a randomised Phase III study of the Italian Lung Cancer Project. f Clin. Oncol 17, 3522–3530 (1999).
   Google Scholar
• ten Bokkel Huinink WW Bergman B, Chemaissani A et al Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer. Lung Cancer26,85–94 (1999).
   PubMedGoogle Scholar
• Bonomi P, Kim KM, Fairclough D et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Co-operative Oncology Group trial. f Clin. OncoL 18,623–631 (2000).
   Google Scholar
• Gatzemeier U, von Pawel J, Gottfried M et al Phase III comparative study of high- dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. J: Clin. Oncol 18,3390–3399 (2000).
   Google Scholar
• Sandler AB, Nemunaitis J, Denham C et al Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer. j Clin. Oncol 18, 122–130 (2000).
   PubMed Web of Science ®Google Scholar
• Frasci G, Lorusso V, Panza N et al Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Co-operative Oncology Group (SICOG) Phase III trial. Lung Cancer 34\(Suppl. 4), S65—S69 (2001).
   Google Scholar
• Kelly K, Crowley J, Bunn PA Jr et al Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J: Clin. Onco1.19, 3210–3218 (2001).
   Google Scholar
• Rosell R, Gatzemeier U, Betticher DC et al Phase III randomised trial comparing paclitaxelicarboplatin with paclitaxel/ cisplatin in patients with advanced non-small cell lung cancer: a co-operative multinational trial. Ann. Oncol 13, 1539–1549 (2002).
   PubMed Web of Science ®Google Scholar
• Souquet PJ, Tan EH, Rodrigues Pereira J et al GLOB-1: a prospective randomised clinical Phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small cell lung cancer patients. Ann. O17C0i 13, 1853–1861 (2002).
   Google Scholar
• Fossella F, Pereira JR, von Pawel J et al Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. Clin. 017C0i 21, 3016–3024 (2003).
   Google Scholar
• Gridelli C, Gallo C, Shepherd FA et al Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: a Phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J: Clin. Oncol 21, 3025–3034 (2003).
   Google Scholar
• Gridelli C, Perrone F, Gallo C et al Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. .1. Nat/ Cancer Inst. 95, 362–372 (2003).
   Google Scholar
• Smit EF, van Meerbeeck JP, Danes P et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: a Phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975.1 Clin. 017C0i 21, 3909–3917 (2003).
   Google Scholar
• Vansteenkiste J, Vandebroek J, Nackaerts K et al Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine. Lung Cancer 40, 191–199 (2003).
   PubMed Web of Science ®Google Scholar
• Wachters FM, Van Putten JW, Kramer H et al First-line gemcitabine with cisplatin or epirubicin in advanced non-small cell lung cancer: a Phase III trial. BE J: Cancer 89,1192–1199 (2003).
   Google Scholar
• Paccagnella A, Favaretto A, Oniga F et al Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non-small cell lung cancer. A multicenter, randomized Phase III trial. Lung Cancer 43,83–91 (2004).
   Google Scholar
• Kubota K, Watanabe K, Kunitoh H et al Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J: Clin. Oncol 22,254–261 (2004).
   Google Scholar
• Buccheri GF, Ferrigno D, Curcio A, Vola F, Rosso A. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Cancer63, 428–432 (1989).
   Google Scholar
• Smith IE, O'Brien MER, Talbot DC et al Duration of chemotherapy in advanced non-small cell lung cancer: a randomised trial of three versus six courses of mitomycin, vinblastine and cisplatin. Clin. Oncol 19,1336–1343 (2001).
   Google Scholar
• Socinski MA, Schell MJ, Peterman A et al Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced stage III/IV non-small cell lung cancer. J. Clin. Onto]. 20,1335–1343 (2002).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R et al Prospective randomised trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J: Clin. Oncol 18, 2095–2103 (2000).
   Google Scholar
• Kosty WIP, Fleishman SB, Herndon JE II et al Cisplatin, vinblastine and hydrazine sulfate in advanced, non-small cell lung cancer: a randomized placebo-controlled, double-blind Phase III study of the Cancer and Leukemia Group B. J. Clin. Oncol 12, 1113–1120 (1994).
   PubMed Web of Science ®Google Scholar
• Agteresch HJ, Dagnelie PC, van der Gaast A, Stijnen T, Wilson JH. Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small cell lung cancer. J. Natl Cancer Inst. 92,321-328 (2000).
   Google Scholar
• Fukuoka M, Yam S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J. din. 017C0i 21,2237–2246 (2003).
   Google Scholar
• Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. j Pineal Res. 35,12–15 (2003).
   PubMed Web of Science ®Google Scholar
• Kaasa S, Mastekaasa A, Thorud E. Toxicity, physical function and everyday activity reported by patients with inoperable non-small cell lung cancer in a randomized trial (chemotherapy versus radiotherapy). Acta Oncol 27,343–349 (1988).
   Google Scholar
• Medical Research Council Lung Cancer Working Party. Inoperable non-small cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br. Cancer 63,265–270 (1991).
   Google Scholar
• Medical Research Council Lung Cancer Working Party. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin. Oncol 8,167–175 (1996).
   Google Scholar
• Ball D, Smith J, Bishop J et al A Phase III study of radiotherapy with and without continuous-infusion fluorouracil as palliation for non-small cell lung cancer. BT. .1. Cancer 75,690–697 (1997).
   Google Scholar
• Stout R, Barber P, Burt P et al Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) versus external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer. Rad Oncol 56,323–327 (2000).
   Google Scholar
• Langendijk H, de Jong J, Tjwa M et al External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomised study. Racl Onco158, 257–268 (2001).
   Google Scholar
• Falk SJ, Girling DJ, White RJ et al Medical Research Council Lung Cancer Working Party. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BT. Med 325,465–468 (2002).
   Google Scholar
• Myrdal G, Vlatysdottir S, Lambe M, Stahle E. Quality of life following lung cancer surgery. Thorax58, 194–197 (2003).
   PubMed Web of Science ®Google Scholar
• Sarna L, Padilla G, Holmes C, Tashkin D, Brecht ML, Evangelista L. Quality of life of long-term survivors of non-small cell lung cancer. Clin. Oncol 20,2920–2929 (2002).
   Google Scholar
• Postoperative Radiotherapy Meta-analysis Trialists Group. Postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet352, 257–263 (1998).
   PubMedGoogle Scholar
• Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BT. Merl 1. 311, 899–909 (1995).
   Google Scholar
• Waller D, Fairlamb DJ, Gower N et al. The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting. Lung Cancer 41\(Suppl. 2), S54, abs 0–179 (2003).
   Google Scholar
• Scagliotti GV, Fossati R, Torn i V et al Randomised study of adjuvant chemotherapy for completely resected stage I, II or Ma non-small cell lung cancer. .1. Nat. Cancer Inst. 95,1453-1461 (2003).
   Google Scholar
• Le Chevalier T, for the IALT investigators. Results of the randomised international adjuvant lung cancer trial (IALT): cisplatin-based chemotherapy (CT) versus no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC). Pmceed Am. Soc. Clin. 017C. 22,2, abs 6 (2003).
   Google Scholar
• Kato H, Tsuboi M, Ohta M et al A randomised Phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I (T1NOMO, T2NOMO) adenocarcinoma of the lung. Proceed. Am. Soc. Clin. 017C. 22,621, abs 2498 (2003).
   Google Scholar
• Roth JA, Atkinson EN, Fossella F et al Long-term follow-up of patients enrolled in a randomised trial comparing perioperative chemotherapy and surgery and surgery with alone in resectable stage Ma non-small cell lung cancer. Lung Cancer21,1–6 (1998).
   PubMed Web of Science ®Google Scholar
• Rosell R, Gomez-Codina J, Camps C et al Preresectional chemotherapy in stage Ilia non-small cell lung cancer: a 7-year assessment of a randomised controlled trial. Lung Cancer 47, 7–14 (1999).
   Google Scholar
• Preoperative chemotherapy in resectable NSCLC. The LU22 protocol. MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK (2002).
   Google Scholar
• Ware JE, Shebourne CD. The MOS 36- item short-form health survey (SF-36). Medical Care 30,473–483 (1992).
   PubMed Web of Science ®Google Scholar
• De Haes JCJM, van Knippenberg FCE, Neijt JR Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. BT. J. Cancer62, 1034–1038 (1990).
   Google Scholar
• Zigmond AS, Snaith RR The hospital anxiety and depression scale. Acta. Bychiatr Scand 67,361–370 (1983).
   PubMed Web of Science ®Google Scholar
• Bailey AJ, Parmar MK, Stephens RJ on behalf of the CHART Steering Committee. Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accellerated radiotherapy (CHART) randomised trial in non-small cell lung cancer. J. Clin. Oncol 16,3082–3093 (1998).
   Google Scholar
• ••Detailed study of the use of area under the curve in the analysis of quality of life (Q0L) data.
   Google Scholar
• Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur. Cancer30, 635–642 (1994).
   Google Scholar
• Furuse K, Fukoka M, Kawahara M et al Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small cell lung cancer. J. Clin. Oncol 17, 2692–2699 (1999).
   PubMed Web of Science ®Google Scholar
• Zatloukal PV, Petruzelka L, Zemanova M et al Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small cell lung cancer. A randomised Phase III study. Proceed. Am. Soc. Clin. Oncol 21, 290a, abs 1159 (2002).
   Google Scholar
• Mornex F, Robinet G, Thomas P et al Sequential versus concurrent chemo-radiation (RT-CT) in locally advanced non-small cell lung cancer (NSCLC): a French randomised Phase III trial of GLOT-GFPC(NPC 95–01 study). Eur.j Cancer 37\(Suppl. 6), S28, abs 93 (2001).
   Google Scholar
• Choy H, Curran WJ, Scott CB et al Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: a randomised Phase II study of three chemo-radiation regimens with paclitaxel, carboplatin and thoracic radiation (TRT) for patients with locally advanced non-small cell lung cancer (LA-NSCLC). Proceed. Am. Soc. Clin. amyl 21,291a, abs 1160 (2002).
   Google Scholar
• Curran WJ, Scott CB, Langer CJ et al Long-term benefit is observed in a Phase III comparison of sequential versus concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proceed. Am Soc. Clin. Oncol 22,621, abs 2499 (2003).
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B et al The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J. Nall Cancer Inst. 85, 365–376 (1993).
   Google Scholar
• Hopwood P, Stephens RJ. Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. BE J. Cancer 71, 633–636 (1995).
   Google Scholar
• Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality of life data. Clin. Oncol 18,893–903 (2000).
   Google Scholar
• Moinpour CM, Lyons B, Grevstad PK et al Quality of life in advanced non-small cell lung cancer: results of a Southwest Oncology Group randomized trial. Qual Life Res. 11,115–126 (2002).
   PubMedGoogle Scholar
• ••Investigation of statistical methods for handling missing data in QOL studies.
   Google Scholar
• Hollen PJ, Gralla RJ, Kris MG et al Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 73,2087–2098 (1994).
   Google Scholar
• Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized Phase III trial. Lung Cancer 43, 183–194 (2004).
   PubMed Web of Science ®Google Scholar
• ••Detailed QOL analyses using sensitivity analyses to confirm primary QOL findings.
   Google Scholar
• Payers P MRC quality of life studies using a daily diary card — practical lessons learned from cancer trials. Qual Life Res. 4, 343–352 (1995).
   PubMedGoogle Scholar
• Stephens RJ, Hopwood P, Girling DJ. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br. Cancer79, 538–544 (1999).
   Google Scholar
• Langendijk JA, ten Velde GPM, Aaronson NK, de Jong JMA, Muller MJ, Wouters EFM. Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int. J. Rad. Oncol Phys. 47,149–155 (2000).
   PubMedGoogle Scholar
• Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality of life scores. 1 Clin. Oncol 16,139-44(1998).
   Google Scholar
• ••Important paper linking change in QOL scores to clinical benefit.
   Google Scholar
• King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res. 5,555–567 (1996).
   PubMed Web of Science ®Google Scholar
• Groenvold M, Payers PM. Testing for differences in multiple quality of life dimensions: generating hypotheses from the experiences of hospital staff. Qual Life Res. 7,479–486(1998).
   PubMedGoogle Scholar
• ••Explores the use of clinicians and nurses to generate predefined QOL hypotheses.
   Google Scholar
• Cella DP, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P Reliability and validity of the Functional Assessment of Cancer Therapy — Lung (FACT-0 quality of life instrument. Lung Cancer 12, 199–220 (1995).
   PubMed Web of Science ®Google Scholar
• Bergner M, Bobbit RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med. Carr 19,787–805 (1981).
   PubMed Web of Science ®Google Scholar
• Morrow GR, Lindke J, Black P Measurement of quality of life in patients: psychometric analyses of the Functional Living Index — Cancer (FLIC). (kat. Life Res. 1,287–296 (1992)
   PubMedGoogle Scholar
• Payers P Quality of life assessment in small cell lung cancer. PharmacoEconomics 2, 181–188 (1992).
   Google Scholar
• Sadura A, Pater J, Osoba D, Levine M, Palmer M, Bennett K. Quality of Life assessment: patient compliance with questionnaire completion. J. Natl Cancer Inst. 84,1023–1026 (1992).
   PubMedGoogle Scholar
• De Haes JCJM, 01schewski M, Payers P et al Measuring the Quality of Life of cancer patients with the Rotterdam Symptom Checklist (RSCL). A manual. Northern Centre for Healthcare Research, University of Groningen, The Netherlands (1996).
   Google Scholar
• Curran D, Aaronson N, Standaert B et al Summary measures and statistics in the analysis of quality of life data: an example from an EORTC-NCIC-SAKK locally advanced breast cancer study. Eur. j Cancer 36,834–843 (2000).
   PubMedGoogle Scholar
• ••Compares and contrasts the use of various summary measures for longitudinal QOL scores.
   Google Scholar
• Qian W Parmar MKB, Sambrook RJ, Payers PM, Girling DJ, Stephens RJ. Analysis of messy longitudinal data from a randomised clinical trial. Statist. Med. 19, 2657–2674 (2000).
   PubMedGoogle Scholar
• Brundage MD, Mackillop WJ. Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966 to 1993.1 Clin. Epidemiol 49,183–192 (1996).
   Google Scholar
• ••Highlights the lack of direction andcollaboration in clinical trial design in the treatment of patients with non-small cell lung cancer.
   Google Scholar